SGLT2 Inhibitors Improve Outcomes in Patients With Diabetes Plus Kidney Disease
Benefits include lower risk for dialysis, hospitalization for myocardial infarction, heart failure, acute kidney injury, and diabetic ketoacidosis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.